Jubilant Pharmova Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

- The company is currently focused on utilizing existing capital for ongoing projects like Spokane Line 4, Montreal Line 5, and PET pharmacies, with a capex in FY2027 expected to be similar to FY2026 (around Rs.1,668 Crores). - There is no indication of any new fundraising planned through debt or equity in the near term; capital allocation is guided by ROCE thresholds and immediate investments are largely committed. - Management expressed commitment to reducing net debt starting FY2028 and achieving net debt zero by FY2030. - The focus is on generating free cash flows from commercialization of products at Line 3 and Line 4 to help deleverage, rather than raising fresh funds. Therefore, no explicit plans for new debt or equity fundraising were disclosed during the call.

The provided transcript from Jubilant Pharmova Limited's Q4 and FY2026 earnings webinar does not explicitly mention current or expected orderbook or pending orders in detail. However, key insights related to business growth and product pipelines include: - The CDMO Sterile Injectables business has about 10+ products in tech transfer on Line 3, with commercial production expected late FY2027, generating $60-$80 million revenue. - Approximately 80% of these Line 3 products are complex biologics, commanding premium pricing. - Ruby-Fill® franchise is rapidly expanding in market size and share, contributing to increasing recurring revenues. - Allergy business growth driven by increased market share and expansion into non-US markets. - Radiopharma's Montreal facility production is stabilizing; first half FY2027 margins impacted temporarily due to supply shortages. - Significant capex ongoing for Spokane Line 4, Montreal Line 5, and PET pharmacies supporting future growth. No direct quantitative orderbook or pending order value disclosures were provided.